Geron (STU:GON) Additional Paid-In Capital : €1,837.89 Mil(As of Mar. 2024)

View and export this data going back to 1996. Start your Free Trial

What is Geron Additional Paid-In Capital?

Geron's quarterly additional paid-in capital declined from Sep. 2023 (€1,721.10 Mil) to Dec. 2023 (€1,691.85 Mil) but then increased from Dec. 2023 (€1,691.85 Mil) to Mar. 2024 (€1,837.89 Mil).

Geron's annual additional paid-in capital increased from Dec. 2021 (€1,237.24 Mil) to Dec. 2022 (€1,409.84 Mil) and increased from Dec. 2022 (€1,409.84 Mil) to Dec. 2023 (€1,691.85 Mil).

Geron Additional Paid-In Capital Historical Data

The historical data trend for Geron's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geron Additional Paid-In Capital Chart

Geron Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

1,093.35

1,123.01

1,237.24

1,409.84

1,691.85

Geron Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															1,660.16	1,661.25	1,721.10	1,691.85	1,837.89

Geron Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Geron Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Geron's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Geron (STU:GON) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (STU:GON) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

GERN:USA

Address

919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404

Website

https://www.geron.com

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.

Geron (STU:GON) Headlines

No Headlines